Sei Investments Co. Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Sei Investments Co. lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 3.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 293,009 shares of the medical research company’s stock after selling 10,962 shares during the quarter. Sei Investments Co. owned 0.22% of Natera worth $46,383,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the period. Geode Capital Management LLC increased its position in Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. lifted its holdings in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after acquiring an additional 269,706 shares during the period. Castle Hook Partners LP increased its position in shares of Natera by 27.4% during the 3rd quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock valued at $144,734,000 after purchasing an additional 245,505 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Natera by 42.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after purchasing an additional 328,375 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $153.83 on Tuesday. The company has a market cap of $20.80 billion, a P/E ratio of -87.40 and a beta of 1.80. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm’s fifty day moving average is $160.92 and its two-hundred day moving average is $150.26.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTRA. BTIG Research restated a “buy” rating on shares of Natera in a research report on Friday, February 28th. Piper Sandler boosted their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Finally, Robert W. Baird raised their price objective on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.12.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,433,183.76. This trade represents a 29.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John Fesko sold 663 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 306,797 shares of company stock valued at $48,940,883 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.